276 related articles for article (PubMed ID: 28004147)
1. Developing anti-neoplastic biotherapeutics against eIF4F.
Steinberger J; Chu J; Maïga RI; Sleiman K; Pelletier J
Cell Mol Life Sci; 2017 May; 74(9):1681-1692. PubMed ID: 28004147
[TBL] [Abstract][Full Text] [Related]
2. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
3. Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.
Bitterman PB; Polunovsky VA
Mol Cancer Ther; 2012 May; 11(5):1051-61. PubMed ID: 22572598
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
Malka-Mahieu H; Newman M; Désaubry L; Robert C; Vagner S
Clin Cancer Res; 2017 Jan; 23(1):21-25. PubMed ID: 27789529
[TBL] [Abstract][Full Text] [Related]
5. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
Lin CJ; Malina A; Pelletier J
Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
[TBL] [Abstract][Full Text] [Related]
6. Translational control of cell fate: from integration of environmental signals to breaching anticancer defense.
Bitterman PB; Polunovsky VA
Cell Cycle; 2012 Mar; 11(6):1097-107. PubMed ID: 22356766
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppression by small molecule inhibitors of translation initiation.
Chen L; Aktas BH; Wang Y; He X; Sahoo R; Zhang N; Denoyelle S; Kabha E; Yang H; Freedman RY; Supko JG; Chorev M; Wagner G; Halperin JA
Oncotarget; 2012 Aug; 3(8):869-81. PubMed ID: 22935625
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
9. Targeting the eIF4F translation initiation complex for cancer therapy.
Konicek BW; Dumstorf CA; Graff JR
Cell Cycle; 2008 Aug; 7(16):2466-71. PubMed ID: 18719377
[TBL] [Abstract][Full Text] [Related]
10. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis.
Lin CJ; Nasr Z; Premsrirut PK; Porco JA; Hippo Y; Lowe SW; Pelletier J
Cell Rep; 2012 Apr; 1(4):325-33. PubMed ID: 22573234
[TBL] [Abstract][Full Text] [Related]
11. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
[TBL] [Abstract][Full Text] [Related]
12. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
[TBL] [Abstract][Full Text] [Related]
13. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
Pelletier J; Graff J; Ruggero D; Sonenberg N
Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
[TBL] [Abstract][Full Text] [Related]
14. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
15. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
16. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
17. Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes.
Huang BP; Wang Y; Wang X; Wang Z; Proud CG
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H505-14. PubMed ID: 19074679
[TBL] [Abstract][Full Text] [Related]
18. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.
Zindy P; Bergé Y; Allal B; Filleron T; Pierredon S; Cammas A; Beck S; Mhamdi L; Fan L; Favre G; Delord JP; Roché H; Dalenc F; Lacroix-Triki M; Vagner S
Cancer Res; 2011 Jun; 71(12):4068-73. PubMed ID: 21498638
[TBL] [Abstract][Full Text] [Related]
19. eIF4F: a retrospective.
Merrick WC
J Biol Chem; 2015 Oct; 290(40):24091-9. PubMed ID: 26324716
[TBL] [Abstract][Full Text] [Related]
20. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
